Table 3 Demographic and clinical factors across rs1501357 Genotypes for Study 2.

From: Evidence for the contribution of HCN1 gene polymorphism (rs1501357) to working memory at both behavioral and neural levels in schizophrenia patients and healthy controls

 

Mean ± SD

F or χ2

P

 

TT/TC

CC

2-back

Controls

0.90 ± 0.15

0.86 ± 0.20

1.789

0.183

Patients

0.73 ± 0.22

0.83 ± 0.11

2.821

0.099

Age

Controls

26.89 ± 5.35

27.95 ± 5.92

1.110

0.294

Patients

28.28 ± 7.62

26.75 ± 8.36

0.433

0.513

Gender (male/female)

Controls

87/27

30/11

0.060

0.807

Patients

35/5

15/1

4.742

0.316

Education (years)

Controls

13.75 ± 3.17

12.71 ± 3.22

3.239

0.074

Patients

12.73 ± 3.22

11.81 ± 2.76

0.991

0.324

PANSS positive

Patients

19.60 ± 6.68

21.50 ± 7.96

0.518

0.477

PANSS negative

Patients

20.88 ± 6.57

17.20 ± 7.57

2.056

0.161

Medication Dose (mg/day)a

Patients

633.13 ± 432.16

640.23 ± 516.47

0.392

0.535

  1. aChlorpromazine equivalents.
Back to article page